R&D Pipeline

Phase:

Therapy:

Pipeline last updated 1 May 2014
Compound/indication Phase 1 Phase 2 Phase 3 Filed
Tresiba® (insulin degludec) (NN1250)

Type 1 and 2 diabetes
Ryzodeg® (insulin degludec and insulin aspart) (NN5401)

Type 1 and 2 diabetes
Xultophy® (IDegLira) (NN9068)

Type 2 diabetes
Faster-acting insulin aspart (NN1218)

Type 1 and 2 diabetes
Semaglutide (NN9535)

Type 2 diabetes
LATIN T1D (NN9211)

Type 1 diabetes
OG217SC (NN9924)

Type 2 diabetes
LAI287 (NN1436)

Type 1 and 2 diabetes
OG987GT (NN9926)

Type 2 diabetes
OG987SC (NN9927)

Type 2 diabetes
OG217GT (NN9928)

Type 2 diabetes
OI338GT (NN1953)

Type 1 and 2 diabetes
  •